Replimune Revenue and Competitors
Estimated Revenue & Valuation
- Replimune's estimated annual revenue is currently $17.8M per year.
- Replimune's estimated revenue per employee is $46,419
- Replimune's total funding is $87M.
- Replimune's current valuation is $1.1B. (January 2022)
Employee Data
- Replimune has 384 Employees.
- Replimune grew their employee count by 19% last year.
Replimune's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder, President and Chief Research & Development Officer | Reveal Email/Phone |
2 | Chief Manufacturing Officer | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | QA Officer | Reveal Email/Phone |
5 | VP Global IT | Reveal Email/Phone |
6 | VP, CMC | Reveal Email/Phone |
7 | SVP Medical Affairs | Reveal Email/Phone |
8 | VP Finance | Reveal Email/Phone |
9 | VP Clinical Development | Reveal Email/Phone |
10 | Head, Global Scientific Engagement | Reveal Email/Phone |
Replimune Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Replimune?
Replimune is working to advance the science of oncolytic immunotherapy to improve on existing therapies and help treat more patients with a variety of tumor types. Oncolytic immunotherapy uses viruses that have been modified to selectively replicate in and kill tumors. Replimunes' goal is to develop powerful therapies to overcome cancer.
keywords:N/A
$87M
Total Funding
384
Number of Employees
$17.8M
Revenue (est)
19%
Employee Growth %
$1.1B
Valuation
N/A
Accelerator
Replimune News
Replimune Group is developing a novel class of tumor-directed oncolytic immunotherapies, according to a press release from the company.
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the...
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the...
WOBURN, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced four poster presentations at the upcoming Society for Immunotherapy of Cancer’s (SITC) 3 ...
Replimune Group Inc., a biotechnology company focused on developing next generation oncolytic immunotherapies, announced today the completion of a $55 million Series B financing. The proceeds of the financing will primarily be used to generate human proof of concept data for its lead product, RP ...
Other Companies in Woburn
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $58.2M | 388 | -1% | N/A |
#2 | $107.2M | 427 | 4% | N/A |
#3 | $168.6M | 438 | 35% | N/A |
#4 | $83.4M | 460 | -4% | N/A |
#5 | $133.1M | 484 | 1% | N/A |